If approved, Luye Pharma's schizophrenia drug LY03010 faces a crowded market

25 November 2022
luye-big

China-based Luye Pharma’s (SEHK: 2186) pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated comparable bioavailability with Johnson & Johnson’s (NYSE: JNJ) Invega Sustenna (1-month paliperidone palmitate) at steady state.

If approved, it will create more options for the management of schizophrenia, but will have to face a crowded LAI market, says data and analytics company GlobalData.

According to GlobalData’s report, “ Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031,” LY03010 is anticipated to be launched in the USA in second-quarter 2024. It is forecast to reach sales of $63.5 million in 2031, representing 0.6% of the US schizophrenia market in 2031.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical